Summary
The pharmacokinetics and metabolism of quinidine were investigated in extensive and poor metabolisers of sparteine. No differences in plasma clearance, terminal half life, volume of distribution or cumulative urinary excretion of quinidine, 3-hydroxyquinidine and quinidine-N-oxide were observed between phenotypes. Thus, it is unlikely that quinidine metabolism is controlled by the sparteine/debrisoquine gene locus.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boobis AR, Murray S, Hampden CE, Davies DS (1985) Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol l'-hydroxylase activities. Biochem Pharmacol 34: 65–71
Dayer P, Balant L, Küpfer A, Striberni R, Leemann T (1985) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first pass metabolism of bufuralol. Eur J Clin Pharmacol 28: 317–320
Eichelbaum M, Spannbrucker N, Dengler HJ (1979) Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur J Clin Pharmacol 16: 189–194
Eichelbaum M, Bertilsson L, Sawe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 31: 184–186
Eichelbaum M (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7: 1–22
Eichelbaum M (1984) Polymorphic drug oxidation in humans. Fed Proc 43: 2298–2302
Idle JR, Smith RL (1984) The debrisoquine hydroxylation gene: A gene of multiple consequences. In: Lemberger L, Reidenberg MM (eds) Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics. American Society for Pharmacology and Experimental Therapeutics, pp 148–164
Inaba T, Nakano M, Otton SV, Mahon WA, Kalow W (1984) A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monoxygenase. Can J Physiol Pharmacol 62: 860–8628
Lennard MS, Silas JH, Freestone S, Trevethick J (1982) Defective metabolism of metoprolol in poor metabolisers of debrisoquine. Br J Clin Pharmacol 14: 301–303
Leroyer R, Jarreau C, Pays M (1982) Specific determination of quinidine and metabolites in biological fluids by reversedphase high-performance liquid chromatography. J Chromatogr Biochem Appl 228: 336–371
Metzler CM (1969) A user's manual for NONLIN. The Upjohn Company Technical Report 7292/69/7292/005, Kalamazoo, Michigan
Otton SV, Inaba T, Kalow W (1982) Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci 32: 795–800
Rowland M, Tucker G (1982) Symbols in pharmacokinetics. Br J Clin Pharmacol 14: 7–13
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intell Publ: 58
Zekorn C, Achtert G, Hausleiter HJ, Moon CH, Eichelbaum M (1985) Pharmacokinetics ofN-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr 63: 1180–1186
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mikus, G., Ha, H.R., Vožeh, S. et al. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur J Clin Pharmacol 31, 69–72 (1986). https://doi.org/10.1007/BF00870989
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00870989